loading
tvc

CHOOSE YOUR TVC LANDING PAGE

Faculty/Inventor/Staff

inventor

Company Representative

partner

University of Utah Startups

University of Utah Startups: An Economic Engine for Utah

Since 1970, the University of Utah has created over 230 spin-off companies from technologies developed at the University, most of which were launched over the past ten years. Over 130 of these are still operating as either a business or as part of another company.

A March 2011 study by the Bureau of Economic and Business Research (BEBR) found that University of Utah startups have either directly or indirectly generated close to 16,000 jobs, many of which are high-paying. The BEBR also found that in 2009 alone, University of Utah spin-offs generated $754.5 million in personal income and $76.6 million in tax revenue. And, since 2011, the University's spin-offs have collectively raised over $300 million in investment funding, secured over $70 million in grants and have been involved in acquisitions totaling more than $5.7 billion.

Use the tools under "Select Category" below to search through profiles of all of the University's active startups. To view more information about a company, click on that startup's box and an abstract containing information about that company will appear. Each abstract contains a contact individual at TVC for you to connect with should you have additional questions about a particular company.

Since 2012, over $5.7 billion has gone towards the acquisition of University of Utah startups. With the recent introduction of our Engine Search Accelerator, we anticipate these kind of liquidity events to be recurring actions in the future.
If you are interested in investing in a University of Utah spin-off currently seeking investment funding, select "Funding Round Forthcoming" under the dropdown menu "Filter by Funding Round". This will bring up a list of those startups currently raising investment funds. From this list, click on the name of each startup to view more information about that company. Contact the name listed under the startup for more information about how to invest in them.
If you would like to get more information about a startup than what is listed in its abstract, we invite you to either visit the company's webpage or connect with the TVC contact listed under that startup's profile
Over 30 of the University of Utah's spin-off companies have been acquired by outside companies. International businesses such as Merck, Shire, Xerox, Raytheon, Teva Pharmaceuticals, nVidia, Rockwell Collins, Allergan, Schlumberger and BioMérieux have each acquired University of Utah startups. To view those startups that have been acquired, choose the options under the "Filter by Acquisition Status" dropdown menu.
Since 2012, University of Utah startups have raised over $200 million in combined investment funding and received over $70 million in grants.

Select Category

» U Startups

EGS

x

Startup: Active Desk

Technology Description: Active Desk is an integrated recumbent exercise bike and desk with refined ergonomics for easy computer operation. Active Desk facilitates physical activity throughout the workday and thus improves physical and psychological health.

Technology Status: In Market

Current Investors:

Investment Stage:

Management Team: Dr. Jim Martin, PhD, FACSM

Year Founded: 2013

Contact: Richard L. Green, Ph.D., JD, 801-213-3573

Website: http://activedeskrider.com

x

Startup: A.D.A.M.

Year Founded: 1987

Acquirer: Ebix Health

Website: www.ebix.com

x

Startup: Add-it

Technology Description: Add-It is developing interactive educational and support tools and devices for children with ADHD. Add-It's software will be available in several modules, from a simple parent alert when assignments are turned in, to the full student application with remote control, allowing the Add-It-enabled device to turn off other electronic devices.

Technology Status: Phase 1

Current Investors: Brain Capital

Investment Stage: Series A

Management Team: Danny Mason CEO. Jodi Groot Chief researcher. Alan Whitaker CTO. Plus a few Ph.D. students

Year Founded: 2012

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://additkids.org

x

Startup: Allegro Diagnostics

Technology Description: Allegro Diagnostics Corp. is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests to support the diagnosis and management of lung cancer. These tests have the potential to enable the early diagnosis, staging and informed treatment of lung cancer and other lung diseases.

Technology Status: Pre-Commercialization

Current Investors: Kodiak Venture Partners, Catalyst Health Ventures, Trustees of Boston University

Investment Stage: Pre-Series B

Management Team: Michael Webb, CEO Duncan Whitney, Sr. VP of R&D

Year Founded: 2008

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: www.allegrodx.com

x

Startup: AlloCure

Technology Description: "AlloCure, Inc. is a pioneer in the development of cell therapies for the treatment of kidney disease and is a leader in the acute kidney injury field. The company's proprietary technology enables the isolation and expansion of mesenchymal stem cells (MSC), obtained via conventional bone marrow donation, which can then be administered off-the-shelf to any patient in need without requiring tissue matching or immunosuppressants. The company's most advanced program, AC607, targeting acute kidney injury, has entered phase 2 clinical development with the initiation of ACT-AKI (AC607 Trial in Acute Kidney Injury), and represents the first cell therapy to treat this potentially life threatening condition."

Technology Status: Phase 2

Current Investors: SV Life Sciences, Novo Ventures and Lundbeck Ventures

Investment Stage: Series B

Management Team: Robert M. Brenner, M.D., President and Chief Executive Officer; John B. Wirthlin, MBA, Chief Operating Officer; Viken Paragamian, BSc, Vice President, Clinical Development

Year Founded: 2006

Contact: Leena Bhoite, Ph.D., 801-213-3581

Website: http://www.allocure.com

x

Startup: Allvivo Vascular

Technology Description: Allvivo Vascular develops biomimetic and antimicrobial coatings for medical devices and combination products. We collaborate with licensees and marketing partners to deliver blood compatible devices and devices that enable responsible infection control. The Gatekeeper™ antimicrobial technology kills bacteria and fungi through a fundamentally different mechanism than antibiotics and will not contribute to the escalating problem of multi-drug resistance. Our mission is to improve medical devices, facilitate cost control, and improve patient outcomes using biocompatible and sustainable antimicrobial technologies.

Technology Status: Prototype

Current Investors:

Investment Stage: Pre-Series A

Management Team: Jennifer A. Neff, Ph.D., CEO

Year Founded: 2000

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.allvivo.com

x

Startup: ApopTx

Technology Description: ApopTx was formed with the goal of developing novel cancer therapeutics that target cancer progression in late stage abdominal and ovarian cancers.

Management Team: Scott Kuwada

Year Founded: 2014

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

x

Startup: Applied Biosensors

Technology Description: Applied Biosensors is aspiring to be the world's leader in the 'continuous biomarker monitoring' industry with a revolutionary technology that is simple yet robust. 'Smart' polymers on an array of micro transducers constitute a standard sensing platform that will be supplied to multiple markets starting with ones that have low regulatory barriers.

Technology Status: Scalable prototype

Current Investors: Proprietary Information

Investment Stage: Pre-Series A

Management Team: Prashant Tathireddy, Rich Barra, Rohit Sharma, Jeff Chance (business advisor)

Year Founded: 2013

Contact: James E. Thompson, M.S., 801-213-3564

x

Startup: Applied Medical Visualizations

Technology Description: Applied Medical Visualizations LLC (Medvis) specializes in the visualization of medical information. The company's products have been demonstrated to improve the comprehension of complex medi- cal data. Its founders have developed and tested state-of-the-art solutions for education, informa- tion presentation, patient monitoring and information management. The company incorporates a user-centered design approach that simplifies user interaction with intuitive presentation and visualization of information. The company's products allow its customers to better manage patient care and ensure patient safety while minimizing cost.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2003

Contact: Richard L. Green, Ph.D., JD, 801-213-3573

Website: http://www.medvis.com

x

Startup: Arapeen Medical

Technology Description: Arapeen Medical is pioneering the use of magnetic resonance guided focused ultrasound in renal sympathetic nerve ablation in the non-invasive treatment of hypertension.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2013

Contact: James E. Thompson, M.S., 801-213-3564

x

Startup: ASHA Vision

Technology Description: Combined management of intraocular pressure and neuroprotection associated with Glaucoma through the use of novel eye drop compounds.

Technology Status: Pre-clinical

Current Investors: Proprietary Information

Investment Stage: Pre-seed

Management Team: Dr. David Krizaj, CEO; Dr. Randall Olson, Chairman; Dr. Dana Ono, Director

Year Founded: 2013

Contact: John Gebhard, Ph.D., 801-213-3564

x

Startup: Attensity Corporation

Technology Description: Attensity is a leading provider of corporate insight solutions based on proprietary data contextualization. As a pioneer in natural language processing and sentiment analysis, Attensity's solutions identify relevant and accurate information from multi-channel data sources using highly sophisticated and patented semantic technologies, analytics and context based discovery. Using Attensity's integrated solutions, enterprise companies can interpret and "understand" massive amounts of structured and unstructured data from many different sources, thereby helping to improve the customer experience, manage brand equity, enhance revenue, mitigate business risk, and help inform business strategies.

Technology Status: In market

Current Investors: Proprietary Information

Investment Stage: Series C and Later

Management Team: Howard Lau – CEO and Chairman; Frank Brown – CFO; Martin Onofrio – CRO; Tommy Hawkins – VP, Development; James Purchase – VP, Product Management; Mike White – VP, Operations; Angela Ausman – Head of Marketing

Year Founded: 2000

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.attensity.com

x

Startup: Synoptic

Technology Description: "Synoptic is a global data hub for geophysical data from weather to oceanography to geology and every discipline in between. Since 2012, Synoptic has been delivering valuable data to NOAA from disparate public and private sources while playing a leading role in the National Mesonet Program. It is currently rapidly expanding the amount of data available and the number of users benefiting from this shared data source.
Synoptic draws on the experience and skills of experts from the U in data management, delivery, and visualization. It builds on the U's MesoWest program, which has provided groundbreaking access to environmental data for the protection of life and property by government agencies, research agencies, and the public for over 15 years. Synoptic expands and improves on the MesoWest capabilities, providing access to data not available in the MesoWest portal, adding additional quality control, and bringing research-level efforts to full operational status. Synoptic's other founding partner, WeatherFlow Inc., has been applying the latest in observational, modeling, and forecasting technology to its clients' most challenging operational problems for over a decade.
Synoptic builds and greatly expands on its founding partners' capabilities to collect, disseminate, and display geophysical data, applying the latest technologies to build towards the most robust and functional geophysical data hub available."

Technology Status: Phase 2

Current Investors: Weatherflow, private individuals, UURF

Investment Stage: Pre-Series A

Management Team: Buck Lyons, CEO

Year Founded: 2012

Funding Round: Synoptic expects to carry out its next round of funding before the end of 2014 and is open to discussions with outside investors.

Contact: Olena Gligorich, Ph.D., 801-213-3578

x

Startup: AvanSci Bio

Technology Description: AvanSci Bio was founded on novel slide-mounted tissue dissection technology co-invented with ARUP and exclusively licensed from the University of Utah. Dr. Geiersbach of ARUP first identified the need to improve their tissue dissection process, and she and Dr. Adey of AvanSci Bio initially collaborated on the technology invention. Co-founders Rob Parry (CEO) and Dr. Nils Adey (CSO) each bring 20-plus years of product development and business management experience to the new venture. The company's strategy is to continue to develop lab automation solutions that significantly improve the quality, productivity and efficiency of laboratory processes.

Technology Status: Early commercialization

Current Investors: Group of private equity investors

Investment Stage: Pre-Series C

Management Team: Rob Parry (CEO), Nils Adey, Ph.D (CSO), Dr. Ronald Weiss, MD, MBA (Board Member)

Year Founded: 2011

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.avanscibio.com

x

Startup: Axon Optics

Technology Description: Axon Optics utilizes patented lens coating technology to create therapeutic eyewear for those with migraine and light sensitivity.

Technology Status: In Market

Current Investors: Proprietary Information

Investment Stage: Series A

Management Team: Brad Katz, MD, PhD; Steve Blair, PhD; Ben Rollins; Virginia Palyka

Year Founded: 2011

Contact: Leena Bhoite, Ph.D., 801-213-3581

Website: http://www.axonoptics.com

x

Startup: Behavioral Health Strategies

Technology Description: Behavioral Health Strategies provides wellness and mental health services to the Salt Lake Valley.

Management Team: Ross Van Vranken

Year Founded: 2014

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

x

Startup: BioEnergenix

Technology Description: BioEnergenix is developing therapeutics for diabetes, obesity and related metabolic diseases. The company's aim is to discover treatments for the cause of the "metabolic syndrome" underlying these conditions, rather than simply treat the resulting effects. Their strategy is based on targeting a specific pathway, identified by University of Utah scientists that regulates cellular metabolism and homeostasis. BioEnergenix has undertaken screening efforts to identify novel compounds which specifically modulate this pathway and is currently conducting preclinical studies of potential therapeutics.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2008

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.bioenergenix.com

x

Startup: BioFire Diagnostics (Idaho Technologies)

Technology Description: BioFire Diagnostics, Inc. (formerly Idaho Technology, Inc.) is a clinical diagnostics company that manufactures and distributes its proprietary diagnostic respiratory panel, FilmArray RP, which operates on its user-friendly FilmArray system, to hospital-based clinical laboratories in the U.S. and E.U. Featuring unmatched usability, the FilmArray's comprehensive respiratory panel tests for 20 viral and bacterial targets in one, 60-minute test. That's a feat that no other product on the market can match. Physicians attain answers sooner. Laboratories maximize productivity and reduce costs. BioFire is continuing to develop a broader test menu for its FilmArray system, including a blood culture ID panel, gastrointestinal panel, and a meningitis panel.

Technology Status: In Market

Current Investors: Acquired

Investment Stage: Acquired

Management Team: Carl Wittwer, Chairman of the Board and Co-founder; Herm Rosenman, Director; Randy Rasmussen, Director, President, Chief Operating Officer and Co- founder; Eric Gorrell, General Counsel and Corporate Secretary; Robert J. Lollini, Chief Financial Officer and Treasurer

Year Founded: 1991

Acquirer: BioMérieux

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.biofiredx.com

x

Startup: Bionic Technologies

Year Founded: 1997

Acquirer: Cyberkinetics

x

Startup: Blackrock Microsystems

Technology Description: Technology environments at each research laboratory are unique and require a high level of customization and integration. Blackrock Microsystems provides enabling tools for the neuroscience, neural engineering and neuroprosthetics research and clinical community worldwide. The tools--all plug-and-play solutions--are built to the clients' requirements or off-the-shelf, with components that seamlessly add to the clients' existing set-ups. Blackrock installs the components, runs the first experiment and then assists in maintaining them for use. The company also looks into ways to help the client improve the performance of the components as data is generated. The company's commercial vision is to lead the market in implantable microsystems, catering to the immediate and future needs of neuroscience research markets.

Technology Status: In Market

Current Investors:

Investment Stage:

Management Team: Florian Solzbacher, Executive Chairman & President; Andy Gotshalk, CEO; Marcus Gerhardt, CFO; Christine Decaria, V.P. of Development and Operations

Year Founded: 2009

Contact: James E. Thompson, M.S., 801-213-3564

Website: www.blackrockmicro.com

x

Startup: Catheter Connections

Technology Description: Catheter Connections is leading a revolution to develop and commercialize newly conceived medical infusion accessory products. These products are designed to protect patients from acquiring infections during infusion therapy, prevent dangerous practices and improve clinical outcomes. Hospital infections are the fourth largest killer in the United States. A device that prevents rather than treats infection is needed. The CathCon Technology Platform consists of a line of products based on the company's antiseptic technology to prevent contamination leading to infections.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2008

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.catheterconnections.com

x

Startup: Central Logic

Technology Description: A typical interfacility patient transfer can take hours, even days, and requires the referring and attending physicians to take a number of cumbersome steps to complete the process. In addition to wasting valuable time, a patient transfer done incorrectly can prevent a patient in need of im- mediate care from getting the required attention to properly diagnose the situation and remedy the problem. Central Logic develops health-care solutions designed to streamline patient transfers and to facilitate critical transfer decisions for physicians and hospital administrative personnel. Central Logic developed a commercial health care product to answer the specific requirements of patient transfers — ForeFront Transfer™. ForeFront Transfer ensures accuracy, saves time and boosts profitability by ensuring all information is properly evaluated, analyzed and recorded for optimal results.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2007

Contact: John Gebhard, Ph.D., 801-213-3564

Website: http://www.centrallogic.com

x

Startup: Cephalon

Year Founded: 1986

Acquirer: Teva Generics

Website: www.tevagenerics.com

x

Startup: Ceramatec

Technology Description: Ceramatec, with three decades of experience, is internationally recognized with an extensive patent portfolio covering its achievements in the fields of ionic solid-state ceramic and aqueous ionic electrochemical technologies. Their core competencies are in: Ionic conducting ceramics, Electrochemistry, Fuel reformation & syntheses, Ceramic coatings and Multi-functional ceramic structures.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 1980

Acquirer: CoorsTek

Contact: James E. Thompson, M.S., 801-213-3564

Website: www.ceramatec.com

x

Startup: Cimarron Software

Technology Description: Cimarron designs and develops innovative and effective work flow systems. We offer a combination of technical and consulting services, a software development kit, and custom system development to meet the needs of our customers. Our systems allow you to track vital experimental, operational, and production information. And best of all, each 21 CFR part 11 compliant system is easily customized to fit your exact needs.

Year Founded: 1996

Acquirer: NNIM LLC

Website: www.cimsoft.com

x

Startup: CIRJ

Technology Description: CIRJ, Inc. is developing novel approaches to targeting solid tumors, using novel nanotherapeutic particles for direct and specific delivery of anti-cancer drugs to the tumor microenvironment.

Technology Status: Pre-prototype

Current Investors: Robert Tien

Investment Stage: Seeding

Management Team: Robert Tien, CEO

Year Founded: 2013

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

x

Startup: CoNextions

Technology Description: Device for reconnecting connective tissue

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2011

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

x

Startup: Converus, Inc.

Technology Description: Converus ("with truth") is committed to providing trustworthy, technological solutions for deception detection. EyeDetect™ is an alternative technology for deception detection that is accurate, cost-effective, efficient, secure and noninvasive. It allows businesses to manage risk and ensure workplace integrity, and assists law enforcement agencies and governments to detect deception.

Technology Status: The commercial release of EyeDetect became generally available in May 2014.

Current Investors: Donald R. Sanborn, University of Utah Research Foundation, Alta Ventures Mexico Fund 1, L.P., Scientific Assessment Technologies, Inc. (David C. Raskin and John C. Kircher)

Investment Stage: Pre-Series A

Management Team: Todd Mickelsen – CEO & President; Greg Parkinson – Chief Software Architect

Year Founded: 2010

Contact: Olena Gligorich, Ph.D., 801-213-3578

Website: http://converus.com

x

Startup: Creative Medical Health, Inc.

Technology Description:

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2012

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://creativemedicalhealth.com

x

Startup: Curza Global

Technology Description: Curza has developed a unique first-in-class series of antimicrobial compounds that kill, disperse and inhibit the growth of bacteria in biofilm communities. Curza's primary focus is on healthcare applications (antibiotics, device coatings, topical agents, etc.) but is also pursuing industrial applications (oil & gas, water, paints & coatings, etc.). Curza's compounds have shown strong efficacy against a broad spectrum of microorganisms including, for example, gram positive, gram negative bacteria and mycobacterium.

Technology Status: Pre-clinical

Current Investors: Proprietary Information

Investment Stage: Series A

Funding Round: Series A, Late 2014

Management Team: Ryan Davies, CEO

Year Founded: 2013

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.curza.com

x

Startup: Cyberkinetics

Year Founded: 1997

Acquirer: Blackrock Microsystems

Website: www.blackrockmicro.com

x

Startup: Domain Surgical

Technology Description: Domain Surgical develops advanced thermal surgical technology. Its FMwand (Ferromagnetic Surgical System) is a surgical device that is based on ferromagnetic heating technology. The FMwand simultaneously cuts and coagulates soft tissue while minimizing collateral tissue damage, without passing electrical current into the patient.

Technology Status: In market

Current Investors: Angel investors and angel investor groups, Private Equity Firm, Management & Board of Directors, BioStar Ventures, OrbiMed

Investment Stage: Series C and Later

Management Team: David J. McNally, Chairman of the Board, Chief Executive Officer, and President; Phillip L. McStotts, Chief Financial Officer; Philip Eggers, Executive Vice President, Research and Development; Curtis Jensen, Vice President, Quality and Regulatory Affairs; Paul Hammond, Vice President, Operations; Gianfranco Bellezza , Vice President, Clinical and Marketing - Europe and Middle East; Ed Hammond, Director of Clinical Programs

Year Founded: 2011

Contact: John Gebhard, Ph.D., 801-213-3564

Website: http://www.domainsurgical.com

x

Startup: e-Sens

Technology Description: e-SENS is disrupting the aqueous chemical sensing field by employing solid-state semiconductor technology to bring to market multi-parameter chemical sensing instruments that leverage patented electrochemical technologies. e-SENS "lab-on-a-chip" products enable fast, simple, accurate, quantitative and multi-parameter profiling of potable water and dramatically reduce the time, cost and inaccuracy associated with legacy single parameter titrimetric and colorimetric chemical sensing approaches.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2011

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.e-sens.com

x

Startup: Echelon Biosciences, Inc.

Technology Description: Since 1997, EBI has retained its commitment to developing novel assays and reagents for lipid research and beyond. At EBI's core is the desire to innovate, thus pushing medicinal research to new limits. EBI provides scientists around the world with the tools they need to cure human disease states for years to come.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 1998

Acquirer: Frontier Scientfic

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.echelon-inc.com

x

Startup: EGS

Year Founded: 1984

Acquirer: Delcam

Website: www.delcam.com

x

Startup: Elute

Technology Description: Elute, Inc. is developing drug-releasing polymer- coated bone grafts used during orthopedic surgeries. Its initial ElutiBone graft addresses surgical infections and promotes bone healing through local, sustained, controlled release of antibiotics.

Technology Status: Pre-clinical

Current Investors: UpStart Ventures and some insiders

Investment Stage: Series A

Funding Round: Series A-2, Q3 2014

Management Team: Kirk Andriano, Ph.D., CEO, BOD, former VP of R&D Histogenics (cartilage repair devices); Dennis Farrar, Chairman, Partner UpStart Ventures, co-founded 13 Utah life science companies (Myriad Genetics to Sera Prognostics); David Grainger, Ph.D., Chief Scientific Officer, BOD, Chair Pharmaceutics & Pharmaceutical Chemistry, Professor of Bioengineering, University of Utah, Scientific Advisor AO Foundation & Synthes; Cheryl Blanchard, Ph.D., BOD, former CSO & Sr. VP of Zimmer; Ashok Khandkar, Ph.D., BOD, BloXR President & CEO, founding CEO Amedica (orthopedic & spine ceramic implants); Philip Davidson, MD, BOD, Park City, UT orthopedic surgeon with early stage company experience; Daniel Liston, VP of Sales & Marketing, 21 years marketing & management with Pfizer; Kristofer Sinclair, Ph.D., Director of R&D; Danielle Hayes, C.P.A., Director of Finance, formerly Axial Biotech

Year Founded: 2011

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://elutinc.com

x

Startup: Episona

Technology Description: Episona is developing an epigenetic-based diagnostic platform for men's personal health profiles. Episona's first diagnostic panel will focus on male factor infertility (MFI) and in vitro fertilization (IVF) outcome.

Management Team: Douglas Carrell, Bradley Cairns

Year Founded: 2014

Contact: Leena Bhoite, Ph.D., 801-213-3581

Website: http://episona.com

x

Startup: Epitel, Inc.

Technology Description: Epitel is committed to providing quality wireless solutions for long-term EEG monitoring in pre-clinical rodent models of seizures and epilepsy. The Epitel EpochTM wireless EEG recording system is used in laboratories world-wide to track EEG. Epitel is developing the EEG PatchTM, a miniature, discrete, long-term monitoring solution for tracking seizures in persons suffering from seizure disorders. The disposable EEG PatchTM may track seizures better than seizure diaries alone, giving epileptologists a more-complete report of a patient's number and duration of seizures.

Technology Status: In market

Current Investors: Proprietary Information

Investment Stage: Pre-seed

Management Team: F. Edward Dudek, PhD, President; Mark J. Lehmkuhle, PhD, CEO/CTO; John Fisher, Electronics Engineer, Founder; Jean Wheeler, Regulatory Engineer

Year Founded: 2008

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.epitelinc.com

x

Startup: Espira

Technology Description: Espira's objective is to develop rapid and inexpensive microfluidics-based tools for clinical and environmental applications.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2011

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.espirainc.com

x

Startup: Evans & Sutherland

Year Founded: 1987

Acquirer: Rockwell Collins

Website: www.rockwellcollins.com

x

Startup: F2 Solutions

Technology Description: F2 Solutions is providing a guidelines- based approach to the management of patients who have unexplained episodes of fainting or falling. Novel algorithms developed at the University of Utah use the most current U.S. and European guidelines to direct clinicians in the treatment of faint and fall patients. Specifically, software developed at the university based on these algorithms instructs physicians and other health-care professionals what diagnostic and testing procedures to use and provides decision support for hospital admission.

Technology Status: In market

Current Investors: Proprietary Information

Investment Stage: Series C and Later

Management Team: John Elsholz, President/CEO; Dr. Michele Brignole, Chief Medical Officer

Year Founded: 2010

Contact: John Gebhard, Ph.D., 801-213-3564

Website: http://www.faintandfall.com

x

Startup: Falgatter Technologies

Technology Description: Fallgatter Technologies designs, builds and sells the first instruments that measure snowflakes using high speed digital photography. These capabilities have been developed to improve scientific understanding of weather forecasting and weather radar, and to provide better diagnoses of precipitation conditions for improved transportation safety.

Technology Status: Scalable prototype

Current Investors: None. Fallgatter Technologies is supported by sales and grants.

Investment Stage: Pre-seed

Management Team: Tim Garrett and Cale Fallgatter

Year Founded: 2012

Contact: Richard L. Green, Ph.D., JD, 801-213-3573

Website: http://fall-tech.com

x

Startup: FFFractionation

Year Founded: 1977

Acquirer: Postnova Analytics

Website: www.postnova.com

x

Startup: GlycoMira Therapeutics

Technology Description: GlycoMira Therapeutics Inc. combines expertise in medicinal and synthetic chemistry, biology and medicine with the track records of seasoned, serial entrepreneurs and business executives focused on the commercialization of unique proprietary inflammation-modulating therapeutics. Launched in 2008, GlycoMira targets treatment of inflammation using patented polysaccharide derivatives of hyaluronic acid.

Technology Status: Prototype

Current Investors: Proprietary Information

Investment Stage: Pre-Series A

Management Team: Glenn D. Prestwich; Thomas P. Kennedy; G. Thomas Heath

Year Founded: 2008

Contact: John Gebhard, Ph.D., 801-213-3564

Website: http://www.glycomira.com

x

Startup: Glycosan Biosystems

Year Founded: 2006

Acquirer: BioTime

Website: www.esibio.com

x

Startup: Granite Mountain Technologies

Technology Description: GMT provides horizontal integrated circuit (IC) solutions across the complete semiconductor marketplace for multi-synchronous ICs. Next generation flows employ relative timing technology which allows seamless integration of multiple timing domains into a single design. This approach provides an average 3X reduction in energy usage, along with substantial additional improvements in performance, area, and noise. Employing GMT multi-synchronous technology through implementation services or partnerships can give your company a substantial competitive advantage. Our solutions scale from conservative half micron mixed signal designs to high performance designs employing the leading edge 32nm process technologies, and will scale well beyond the 2020 technology nodes.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2011

Contact: Sripriya Raghavendran, MSEE, 801-585-3610

Website: http://www.gmt-semi.com

x

Startup: HeavyStone Labs

Technology Description: Heavystone Lab is an early stage company that is actively engaged in innovation and commercialization of hard and superhard materials technology including cemented tungsten carbide (hardmetals, WC-Co) and polycrystalline diamond. One of the technologies that is gaining momentum is a patented process technology by which WC-Co with a cobalt gradient from surface to the bulk is created. Any existing WC-Co tools can be processed to obtain such a hard surface-tough core structure so that the tools can last significantly longer or able to sustain substantially more impact. Industrial use-tests in rock drilling, machining, and construction have all yielded performance gains from 30 to 100 percent.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2008

Contact: Olena Gligorich, Ph.D., 801-213-3578

Website: http://heavystonelab.com

x

Startup: iBiologics

Technology Description: iBiologics provides high-quality research- grade products for the biotechnology, pharmacology and academic communities.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2012

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://ibiologics.com

x

Startup: Innoception Technologies

Technology Description: Innoception is creating a system to facilitate an online self-tracking for health utility and offers it to the Integrative Health community for development and maintenance.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2011

Contact: James E. Thompson, M.S., 801-213-3564

x

Startup: Iomed

Year Founded: 1977

Acquirer: DJO Global

Website: www.djoglobal.com

x

Startup: iVeena

Technology Description: iVeena, LLC, is an early stage biotechnology company with the mission of developing a novel proprietary drug-delivery device, called the Capsule Drug Delivery Ring, for treatment of the opthalmic diseases. iVeena hopes to change the way eye diseases are treated and improve the quality of life of more than 1 million people per year in the United Sates and potentially 3 million per year worldwide by preserving their vision and simplifying treatment.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2010

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.i-veena.com

x

Startup: Javali

Technology Description: Javali is commercializing a tool for medical chart review.

Year Founded: 2014

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

x

Startup: JSK Therapeutics

Technology Description: JSK Therapeutics, JSKT, is an early stage pharmaceutical company created to develop a new class of cancer treatment drugs which exploit nitric oxide release to selectively kill cancer cells. The company has exclusive licenses for the proprietary agents, their use in cancer treatment and formulation technology. The company has been granted Orphan Drug Designations for use in Acute Myeloid Leukemia and Multiple Myeloma. The class of compounds constitute a pipeline with the lead compound, designated JS-K, in the pre-IND stage of development.

Technology Status: Pre-clinical

Current Investors: Proprietary Information

Investment Stage: Pre-Series A

Management Team: Dr. Paul Shami, Dr. Thomas Kennedy, Gregory Johnson, Dr. Brent Edington, Andrew Sayko

Year Founded: 2009

Contact: John Gebhard, Ph.D., 801-213-3564

x

Startup: Larada, Inc.

Technology Description: Larada Sciences is a Salt Lake City, Utah-based company dedicated to the eradication of head lice. It has built the world's largest network of lice-removal professionals. Its flagship product, the FDA-cleared AirAllé™ device, kills head lice and 99.2 percent of their eggs in a single, 30-minute treatment.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2007

Contact: Richard L. Green, Ph.D., JD, 801-213-3573

Website: http://www.airalle.com

x

Startup: Lazarus Medical

Technology Description: LMT specializes in developing a repositionable drainage system that will traverse the thoracic cavity to improve complete evacuation of unwanted fluid from pleural space. The chest tube has a wide range of movement compared to the existing fixed tubes.

Technology Status: Pre-clinical

Current Investors: Proprietary Information

Investment Stage: Series A

Funding Round: Series A, July 2014

Management Team: Harrison Lazarus MD – CEO; Chris McDowell – COO; Annette McClellan – Advisor; Shawn Fojtik - Advisor

Year Founded: 2012

Contact: Leena Bhoite, Ph.D., 801-213-3581

x

Startup: Lineagen

Technology Description: LineaGen is a diagnostic service and research company focused on diseases for which early diagnosis and intervention have the potential to significantly improve outcome. The company concentrates on three main areas — autism, multiple sclerosis (MS) and chronic obstructive pulmonary disease (COPD) — where access to the Utah Population Database (UPDB) has yielded strong proprietary marker data. LineaGen is in the process of building its capability to offer a best- in-class diagnostic evaluation service and high-quality genetic counseling along with other critical specialist services, that when combined with its strong IP portfolio will help the company to deliver better, more personalized care for patients and their caregivers.

Technology Status:

Current Investors:

Investment Stage:

Funding Round: Series C, spring-summer 2014. Lineagen is seeking up to $7.4M in equity commitments from new investors to invest alongside $3.6M of equity that has been committed from existing investors.

Management Team: Michael Paul (CEO), Gayland Moffat (COO and President)

Year Founded: 2005

Contact: Leena Bhoite, Ph.D., 801-213-3581

Website: http://www.lineagen.com

x

Startup: Live Wire Test Laboratories

Technology Description: LiveWire was founded in 2003 by a team led by Dr. Cynthia Furse who were committed to discovering an advanced and easy-to-use method for identifying the location of faults in electrical wiring systems. The LiveWire technology, spread spectrum time domain reflectometry (SSTDR), can directly detect and locate static and intermittent wiring problems while the wires are energized or live. LiveWire focused its efforts initially in military and aerospace applications, but subsequently expanded its applications to transportation, utility and semiconductor testing including the detection and reporting of electric cable theft, a worldwide problem. The pallet of applications continues to grow as the world becomes "more electric" and LiveWire's technology will be critical to the forthcoming "internet of things" and ultimately provide for the advance notification of electric component failures.

Technology Status: ASIC equipped hand-held devices – commercialized products currently being sold, Modules – Phase 1, Embedded products – Pre-prototype

Current Investors: Founders, Management, Friends & Family

Investment Stage: Series A

Management Team: Cynthia Furse, Chairperson of Board; Ron Vogel, CEO; David Lamb, COO; James Stephenson, PhD, Chief Scientist; Marji Ketaily, Director of Operations

Year Founded: 2006

Contact: Sripriya Raghavendran, MSEE, 801-585-3610

Website: http://www.livewiretest.com

x

Startup: Lone Star Thiotherapies

Technology Description: LoneStar Thiotherapies is commercializing dithiocarbamate/metal complexes as treatment for human hepatobiliary diseases. Thiocarbamates and metals accumulate in the liver, naturally producing therapeutic drug concentration in the hepatic compartment.

Technology Status: Pre-prototype

Current Investors: Proprietary Information

Investment Stage: Pre-seed

Management Team: Andy Sayko, President

Year Founded: 2012

Contact: John Gebhard, Ph.D., 801-213-3564

x

Startup: LV Partners

Year Founded: 2007

Acquirer: Lineagen

Website: www.lineagen.com

x

Startup: MacroMed

Year Founded: 1989

Acquirer: Protherics

x

Startup: Merisight

Technology Description: Marrek was created to meet the large and growing demand for technologies to guide and optimize the treatment of an abnormal heart rhythm known as atrial fibrillation. The company's mission is to be the leader in personalizing and improving the management of cardiac arrhythmia disease throughout the world. They are achieving their objective by developing techniques utilizing magnetic resonance imaging (MRI) that characterize and quantify the stage of disease (fibrosis) in patients with atrial fibrillation. Their Merisight Service assists the physician in personalizing and selecting treatments for their patients, while improving quality outcomes and decreasing health care costs. More than 14 million Americans experience abnormal heart rhythms, and in 4-5 million of these people this arrhythmia is atrial fibrillation, which is characterized by an irregular and usually very rapid heartbeat. The foundational technology was developed by an interdisciplinary team of physicians and medical imaging experts led by U cardiac electrophysiologist Nassir Marrouche, M.D. This team is also exploring the role of fibrosis in other organs as well including their impact on overall health and wellness of the patients they serve.

Technology Status: FDA-compliant, 510(k) cleared medical device; CE-marked

Current Investors: Proprietary Information

Investment Stage: Seed

Management Team: Nassir F Marrouche, MD, Chairman; Nathan Burgon, MBA, VP Services & Innovation (acting managing director); Kevin Tek, Director of Screening and Services

Year Founded: 2009

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://marrekinc.com

x

Startup: MedAnalytics (Formerly NAPE)

Technology Description: MedAnalytics is a Big Data play in the healthcare space. MedAnalytics is providing free online content capabilities for Medical Professional Continuing Education events in return for the ability to own the data flow of the content and interactions between student physicians, medical professionals, teachers, and key opinion leaders. Monetization of the data flow is accomplished by selling the resulting analytics as business intelligence to the medical industry. Access to the content is assured by the front end CME-specific Costumer Relationship Management (CRM) and Learning Management System (LMS) created by MedAnalytics.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2005

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://sites.google.com/a/medanalytics.com/public/

x

Startup: MedQuest Products

Year Founded: 1999

Acquirer: World Heart Corporation then HeartWare

Website: www.worldheart.com

x

Startup: MedVantage Corporation

Technology Description: MedVantage is developing a unique surgical product in the microvascular surgery space. The technology is a vascular coupling system that allows for efficient coupling of arteries and veins in a fraction of a time.

Year Founded: 2013

Contact: Leena Bhoite, Ph.D., 801-213-3581

x

Startup: MultiFunctional Imaging

Technology Description: MFI provides technologies for advanced medical imaging applications, offering solutions for obtaining and quantifying multiple imaging results in a single scan.

Technology Status: Active development of our first product targeting FDA 510(k) submission Fall 2014; several other products in prototype stages.

Current Investors: Four founder investors

Investment Stage: Series A

Management Team: Dave Dolan, CEO; Dan Kadrmas, Founder & Chief Science Officer; Phil Triolo, Regulatory & QA Officer

Year Founded: 2012

Contact: Sripriya Raghavendran, MSEE, 801-585-3610

Website: http://www.multifunctionalimaging.com

x

Startup: Myriad Genetics

Technology Description: Myriad offers an array of genetic tests, prognostic tests and personalized medicine tests to help healthcare providers assess a patient's increased cancer risk, disease aggressiveness and optimize efficacy of chemotherapy. Myriad's testing products can provide healthcare providers with information to help make medical management decisions to reduce cancer risk and help make sure specific treatments are tailored for each individual patient.

Technology Status: In Market

Current Investors: Public

Investment Stage: Public/Acquired

Management Team: Peter D. Meldrum , President and CEO; Mark C. Capone, President; James S. Evans, Chief Financial Officer; Ralph L. McDade Ph.D., President; William Hagstrom, President; Robert G. Harrison , Chief Information Officer; Jayne B. Hart , Executive Vice President, Human Resources; Gary A. King , Executive Vice President, International Operations; Jerry Lanchbury Ph.D. , Chief Scientific Officer; Richard Marsh, Executive Vice President, General Counsel and Secretary; Richard Marsh, Executive Vice President, General Counsel and Secretary

Year Founded: 1992

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.myriad.com

x

Startup: Nano-Oxides

Technology Description: Nano-Oxides, Inc. is working on a patented technology for the synthesis of nanosized oxide powders by molecular decomposition.

Technology Status: Under development

Current Investors: Proprietary Information

Investment Stage: Proprietary Information

Management Team: Dinesh Shetty, Ph.D.; Anil Virkar, Ph.D.

Year Founded: 2008

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.nano-oxides.com

x

Startup: Nanomedic

Technology Description: Excessive iron stored in the body is a powerful catalyst for the generation of highly toxic free radicals that can damage all molecular classes found in vivo. The progression of many diseases such as atherosclerosis, cancer, diabetes, and neurogeneration disorders can be arrested by depleting the excessive iron. The invention uses nanoparticle-conjugated chelators that are delivered to diseased organs to sequester or deplete iron. The conjugated nanoparticles can be biodegradable or non-biodegradable depending on the targeted organ. The targeting capabilities of the system can be further optimized by changing the surface properties of the nanoparticles--by coating surfactants, adding functional groups or linking antibodies. The technology can also be used in radiation therapy and diagnosis. The nanoparticle/chelator system can bind to metals and can serve as imaging agents or pharmaceuticals.

Technology Status: Pre-clinical

Current Investors: Drs. Ping Men and Gang Liu

Investment Stage: Pre-seed

Management Team: Drs. Ping Men and Gang Liu

Year Founded: 2009

Contact: Leena Bhoite, Ph.D., 801-213-3581

x

Startup: Neuroadjuvants

Technology Description: NeuroAdjuvants, Inc. was formed in July 2005 to develop and commercialize novel neuropeptide-based therapeutics for the treatment of neurologic disorders. The Company's novel technologies facilitate the movement of neuropeptides across the blood-brain-barrier. NeuroAdjuvants is initially focused on developing therapies for pain and epilepsy. Epilepsy affects approximately fifty (50) million people worldwide with a market size estimated at more than $3 billion. Only 70% of patients are effectively treated with currently available anticonvulsant drugs. Thus, there is an unmet need for new therapeutic strategies for the symptomatic treatment of epilepsy. There are an estimated 40 million neuropathic pain patients worldwide with total sales exceeding $2.6 billion in 2006 and 10% expected annual growth. Neuropathic pain product sales are projected to surpass $7 billion within the next 10 years.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2006

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

x

Startup: NeuroCircuit Therapeutics

Technology Description: Neurocircuits was formed for the purpose of commercializing a class of compounds that show potential for improving brain function and cognition in Down syndrome and related conditions.

Year Founded: 2014

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: www.neurocircuittherapeutics.com

x

Startup: NeuroVersity

Technology Description: NeuroVersity provides curricula for training programs that help older children with autism turn their natural strengths into highly sought after abilities and technical skills.

Year Founded: 2014

Contact: Richard L. Green, Ph.D., JD, 801-213-3573

x

Startup: NPS Pharmaceuticals

Technology Description: NPS Pharmaceuticals is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company's lead product, Gattex® (U.S.)/Revestive (EU) 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection is approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted its Biologic License Application to the U.S. Food and Drug Administration in October 2013.

Technology Status: In market

Current Investors:

Investment Stage:

Management Team: Francois Nader, MD, President and Chief Executive Officer; Luke M. Beshar, CPA, Executive Vice President and Chief Financial Officer; Paul Firuta, MBA, President, US Commercial Operations; Robin D. Friedman, Senior Vice President, Human Resources; Roger J. Garceau, MD, FAAP, Executive Vice President and Chief Medical Officer; Susan E. Graf, RPh, Vice President, Corporate Development & Strategy; Christine Mikail, JD, Senior Vice President, Legal Affairs, General Counsel and Secretary; Eric Pauwels, Senior Vice President and President, NPS Pharma International; Joseph J. Rogus, PE, Senior Vice President, Global Technical Operations and Supply Chain Management

Year Founded: 1986

Acquirer: Shire

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: www.npsp.com

x

Startup: Ore to Metal Technologies

Technology Description: Ore to Metal Technologies provides technology-based services to the mineral processing industry. They offer an array of software and consulting services to optimize AG/SAG mill operations and are proud to distribute MillSoft, a mill-modeling tool developed by U professor Raj Rajamani.

Technology Status: In market

Current Investors: Proprietary Information

Investment Stage: Series A

Management Team: Don Eggert, Philippe Blot

Year Founded: 2013

Contact: Olena Gligorich, Ph.D., 801-213-3578

Website: http://www.o2mtech.com/Public/

x

Startup: Orriant

Technology Description: Orriant strives to provide increased wellness for individuals, for businesses, and for the community as a whole. The company provides physical, mental, and fiscal wellness opportunities to the American workforce./p>

Year Founded: 2014

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: www.orriant.com

x

Startup: PartNet

Technology Description: Launched in 1992 as a research effort for the Defense Advanced Research Projects Agency (DARPA), Partnet is the expert in online marketplaces for government — providing cost-effective, web-based solutions that enable more efficient government-to-business, government-to-citizen, and government-to-government connections.

Technology Status: In market

Current Investors:

Investment Stage:

Management Team:

Year Founded: 1992

Acquirer: GHX Healthcare

Contact: Olena Gligorich, Ph.D., 801-213-3578

Website: http://partnet.com

x

Startup: Perfect Vision

Technology Description: Three million Americans a year have cataract surgery. While very successful, 10 percent complain of glare related to the new intraocular lens that has been placed in their eye as part of this procedure, and up to 10 percent would like a better refractive result (better vision without needing glasses). This is especially true for those who have previously had refractive surgery like LASIK, PRK and RK because our ability to predict the correct lens power is limited in such cases. The invention is a low-profile intraocular lens that can be placed in the eye after cataract surgery for the correction of all refractive error and disabling glare. The surgery can use the original incision and would take a matter of minutes. Refractive accuracy would be very precise and the new lens is easily replaced at any time if the eye changes in its refractive needs. It could also be used to create multifocality (see far and near without other correction).

Technology Status: Pre-Prototype

Current Investors: Partners Needed

Investment Stage: Pre-Seed

Management Team: Randall Olson, MD

Year Founded: 2011

Contact: John Gebhard, Ph.D., 801-213-3564

x

Startup: PFO Technologies

Year Founded: 2008

Acquirer: Coherex

Website: www.coherex.com

x

Startup: Pharmanex

Year Founded: 2000

Acquirer: NuSkin

Website: www.nuskin.com

x

Startup: Polevault Media (formerly Angry Duck Productions)

Technology Description: Polevault is a new portal for art and technology students to receive real world experience in creating works for real world clients. The company can produce almost anything in the design world: websites, museum exhibit displays, full length movies, marketing collateral, the list goes on. The company works in a cycle. They hire University students to produce works for clients. The students gain real-world experience and the company gains a profit. The profit goes towards educating more students within the College of Fine Arts. These educated students join the Polevault team and the cycle begins again.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2007

Website: http://www.polevaultmedia.com

x

Startup: Predictive Medical

Technology Description: Predictive Medical has created an electronic ICU surveillance platform and has five diagnostic tests in its development pipeline. All five of the tests are for use in the hospital critical care environment. Each test can predict the 24-hour likelihood of a particular adverse outcome. The five diagnostic tests are cardiopulmonary arrest, respiratory failure, renal failure, sepsis and re-intubation risk. These diagnostics are software algorithms designed to operate on patient data already collected by the hospital EMR and patient monitoring systems. There is no new "device" required to run these tests and there is no new sampling required. Diagnostics take only seconds to run and, in practice, are run continuously, automatically alerting the clinicians when there are positive results.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2010

Contact: John Gebhard, Ph.D., 801-213-3564

Website: www.predictivemedical.com

x

Startup: Proactive Memory Services Inc. (PAMS)

Technology Description: Proactive Memory Services is developing a tablet computer and smartphone application to help individuals with memory concerns and their families. The application provides information to people even before they have decided to seek medical attention and throughout their illness. It provides the personalized advice of experts about services that match an individual's needs. The application supports family members in coordinating care, identifies milestones for achieving treatment goals, and helps assess the quality of care received. Alzheimer's disease and related disorders are a growing problem. Patients and families often confront a confusing and complex health system. Proactive Memory Services is engaged in aiding patients and their families in navigating the course of their disease. It utilizes the principles of precision and proactive care developed in partnership with the University of Utah Center for Alzheimer's Care, Imaging, and Research (CACIR).

Technology Status: Phase 1. Application for Phase 2 funding has been submitted.

Current Investors: National Institute on Aging

Investment Stage: Pre-Clinical

Management Team: Norman Foster, M.D., President; Troy Andersen, LCSW, Vice President; Edward Zamrini, M.D., Vice President; Karen Mara, Secretary-Treasurer

Year Founded: 2009

Contact: John Gebhard, Ph.D., 801-213-3564

x

Startup: Process Instruments

Technology Description: Process Instruments was founded in 1994 to develop Raman spectroscopy instrumentation specifically for industrial process monitoring. We brought together a development team focused on the design of state-of-the-art, affordable, frequency-stabilized, narrow-linewidth diode lasers and efficient, optically fast (f/2.0) spectrographs for use in industrial process control applications.

Technology Status: In market

Current Investors: Employee Owned

Investment Stage: Employee Owned

Management Team: Lee Smith, CEO

Year Founded: 1995

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.process-instruments-inc.com

x

Startup: Progenitor Life Sciences

Technology Description: Progenitor is focused on the development and marketing of research tools and molecular diagnostics for the stem cell market.

Year Founded: 2014

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://progenitorlifesciences.com

x

Startup: Q Therapeutics

Technology Description: Q Therapeutics is a biopharmaceutical company that utilizes cell-based technologies to develop new treatments for debilitating diseases of the central nervous system (CNS). The company's first product, called Q-Cells®, is designed to address a wide range of diseases, including multiple sclero- sis (MS), transverse myelitis, ALS (Lou Gehrig's Disease), cerebral palsy, spinal cord injury, traumatic brain injury, stroke, Parkinson's Disease and Alzheimer's Disease. The company's patented cellular technologies and manufacturing processes, combined with an experienced management team and a focused strategy, will enable it to develop a comprehensive product pipeline to treat CNS diseases in ways no existing drug can.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2003

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.qthera.com

x

Startup: RayScale

Year Founded: 2007

Acquirer: nVidia

Website: www.nvidia.com/page/home.html

x

Startup: Recursion Pharmaceuticals

Technology Description: Recursion Pharmaceuticals has developed a unique drug discovery platform using advanced computational algorithms to discover new uses for known therapeutics.

Year Founded: 2014

Contact: John Gebhard, Ph.D., 801-581-6310

Website: www.recursionpharma.com

x

Startup: Resolution Applications

Technology Description: Resolution Applications was formed in early 2013 to license the Faculty Activity Reporting Suite (FAR Suite) application from the University of Utah. Resolution Applications has been actively commercializing the product and is seeking pilot partners to help develop additional functionality and expand the product base. The FAR Suite has been in use at the University of Utah for over 4 years, for approximately 1,300+ faculty distributed across 17 colleges over a hundred departments, and was specifically designed to address the needs of administrators by consolidating all faculty data into one repository, then leveraging that data in a variety of applications, including the Faculty Activity Report, Faculty Profiles, Find a Researcher, Self Service, and Reports. Resolution Applications is solely focused on providing solutions to simplify the collection, management, and use of faculty data for Higher Education. The FAR Suite has been very successful and was designed from inception to be intuitive and easy to use. It is also the only Faculty Activity product that delivers flexible configuration at the college and department level.

Technology Status: Completed, actively marketing our solution, contract signed with first customer

Current Investors: Jeremy Uffens, David Sexton, Adam Howsley, Tyler Pingree

Investment Stage: Pre-seed

Management Team: Jeremy Uffens, David Sexton, Adam Howsley, Tyler Pingree

Year Founded: 2013

Contact: Olena Gligorich, Ph.D., 801-213-3578

Website: http://www.resolutionapplications.com

x

Startup: Respiris

Year Founded: 2006

Acquirer: Lineagen

Website: www.lineagen.com

x

Startup: Rosetta Inpharmatics

Year Founded: 1996

Acquirer: Merck

Website: www.merck.com/index.html

x

Startup: RU Ready

Technology Description: RUReady is an interactive and self-paced online learning program that truly engages students in learning the math necessary for college level courses. RUReady is the needed solution for bridging the academic gap between high school and college curriculum. Are high school seniors ready for college? According to the Alliance for Excellent Education, only 34% of students who graduate from high school are ready for college. For mathematics and other math-based courses, RUReady has the answer. RUReady's technology empowers teachers to implement state and national curriculum standards while allowing customizing the learning process according to both the student's needs and interests. RUReady's proprietary parser allows students to answer open-ended math questions in a way that is not possible in other learning systems.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2008

Contact: Olena Gligorich, Ph.D., 801-213-3578

x

Startup: Salarius Pharmaceuticals

Technology Description: Salarius Pharmaceuticals is developing the only reversible lysine specific histone demethylase 1 inhibitors (LSD1) which are close to early clinical studies, expected to start in 2015. Our compound SP-2577 has strong potential to help cancer sufferers in certain sarcomas like Ewing's sarcoma, acute myeloid leukemia (AML), prostate cancer and triple negative breast cancer and others, where it may be effective in stem-like cancers where many other therapies have failed.

Technology Status: In regulatory studies directed to support filing of an Investigational New Drug Application

Current Investors: Investment has been from the founders, friends and family and a few high net worth individuals

Investment Stage: Pre-Series A

Management Team: Jonathan Northrup, CEO & Founder; Sunil Sharma, MD, FACP, Founder

Year Founded: 2012

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.salariuspharma.com

x

Startup: Sarcos

Year Founded: 1983

Acquirer: Raytheon

Website: www.raytheon.com

x

Startup: Sentius Technology

Technology Description: Sentius is engaged in developing a simple to use business analytic tool that acts on gathering relevant data, analyzing the data, and delivering actionable information on that data.

Year Founded: 2014

Contact: John Gebhard, Ph.D., 801-213-3564

Website: www.sentiusdata.com

x

Startup: SentrX Animal Care

Technology Description: SentrX Animal Care is a 8-year old science-driven, evidence-based company selling tissue repair products for animal health under the SentrX brand in Turkey, Taiwan and China, by Orion Pharmaceuticals (Helsinki) in the Nordic, Russian Federation and Eastern European countries and by Bayer Animal Health in the US, Ireland, UK, Germany and Austria. Other countries are in negotiation. All sales are under exclusive licenses. In the US, Bayer sells equine and small animal versions, and DVM and OTC versions of the latter. Products are sold under the Aptus (Orion), Remend (Bayer), or SentrX brands. SentrX currently manufactures three gel products for epithelial wounds, dry eye, and corneal repair. All but the KCS product, which was introduced in early 2013, have been used in more than 100,000 cases without any reported negative effects. The products are all produced by SentrX under sterile manufacturing conditions. The core chemistry is a carboxymethyl thiolated, cross-linked hyaluronic acid that is globally patented. These chemical modifications provide stability and are slightly different in each product, in order to achieve desired rheology. Details of the chemistry can be found at www.sentrxanimalcare.com.

Technology Status: In Market

Current Investors: Proprietary information

Investment Stage: Not seeking investment

Management Team: Richard K. Koehn, Ph.D., President and CEO; Brenda Mann, Ph.D., Vice-President for Research; Sarah Atzet, Ph.D., Chief Operating Officer

Year Founded: 2006

Contact: John Gebhard, Ph.D., 801-213-3564

Website: http://www.sentrxanimalcare.com

x

Startup: Sentrx Surgical, Inc.

Year Founded: 2005

Acquirer: Carbylan

Website: http://carbylan.com

x

Startup: Sera Prognostics

Technology Description: The company was launched to commercialize a joint invention by inventors at the University of Utah and Brigham Young University. The company is developing a diagnostic platform for pre-eclampsia, a pre-term pregnancy disorder in which the mother suffers from high blood pressure induced by the pregnancy. It is one of the more common dangerous pregnancy complications and was highlighted recently in the premature birth of Jim and Michelle Duggar's 19th child (of "19 Kids and Counting" fame).

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2009

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.seraprognostics.com

x

Startup: SimplicityMD Solutions

Technology Description: SimplicityMD Solutions is developing simple class I medical devices that improve health care while reducing cost. They are currently in the product development stage of designing a chest tube securement device and a securement device for an internal jugular catheter.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2013

Contact: Leena Bhoite, Ph.D., 801-213-3581

x

Startup: Solan PV

Technology Description: Solan is bringing to market exciting graphene technology by bridging the gap between materials research and commercial applications.

Technology Status: Scalable prototype

Current Investors: Sorenson Capital, Ritchie Group, University of Utah

Investment Stage: Series A

Management Team: Brandon Lloyd, VP of Development (acting CEO); Mark Davis, Solan CTO and semi-conductor manufacturing expert; Numerous top graphene researchers and materials scientists at the University of Utah

Year Founded: 2010

Contact: Timothy Tripp, JD, 801-581-8057

Website: http://www.solanpv.com

x

Startup: Symptomly

Technology Description: Symptomly has developed eAsthma Tracker to address the needs of child asthma patients. The platform includes mobile and internet patient/physician portals, focused care coordination through tracking, and active communication and notification.

Year Founded: 2013

Contact: John Gebhard, Ph.D., 801-213-3564

Website: http://symptomly.com

x

Startup: Tactical Haptics

Technology Description: Tactical Haptics was founded to commercialize haptic feedback technologies. The initial focus of the company is on commercializing the use of Reactive Grip™ Tactile Shear Feedback in the fields of virtual reality, gaming, and medicine.

Year Founded: 2013

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://tacticalhaptics.com

x

Startup: Techcyte

Technology Description: Techcyte provides a digital pathology solution for segmenting hematopoietic cells for more effective and efficient analysis of blood and bone marrow cells via digital image analysis and categorization utilizing machine-learning algorithms.

Year Founded: 2013

Contact: James E. Thompson, M.S., 801-213-3564

x

Startup: Telomere Diagnostics

Technology Description: Telomere Diagnostics is a biotechnology company committed to a deeper understanding of telomere science and how it might promote human health, assess disease risk and predict drug response.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2011

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.telomehealth.com

x

Startup: Tepnel Lifecodes

Year Founded: 1988

Acquirer: Immucor

Website: www.immucor.com/en-us/Pages/Main-Page.aspx

x

Startup: TerraTek

Year Founded: 1970

Acquirer: Schlumberger

Website: www.slb.com

x

Startup: TheraTarget

Technology Description: TheraTarget is an emerging biopharmaceutical drug delivery company developing a variety of polymer-drug conjugates utilizing our nanopolymer drug delivery technologies.

Technology Status: A combination of pre-prototype (research and development)and prototype stages

Current Investors: Proprietary Information

Investment Stage: Pre-seed

Funding Round: Series A, Fall 2014

Management Team: Henry Kopecek, Hamid Ghandehari, Chang Ahn, Matt Peterson, and Sunil Sharma

Year Founded: 2009

Contact: John Gebhard, Ph.D., 801-213-3564

Website: http://www.theratarget.com

x

Startup: TheraTek

Year Founded: 1989

Acquirer: Watson Pharmaceuticals then Actavis

Website: www.actavis.com

x

Startup: Tramontane, Inc.

Technology Description: Biostratigraphic data are highly complex! Microfossils are commonly mixed in deep-water depostional settings. Tramontane has developed TACSWorks to provide biostratigraphers with the tools necessary to get the most from their data. TACSWorks consists of three interactive windows that can simultaneously display analytical results, a distribution chart, and multiple wells in cross section.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2001

Contact: Olena Gligorich, Ph.D., 801-213-3578

Website: http://tramontaneinc.com

x

Startup: TransViragen

Technology Description: TransViragen is a premier provider of services for the generation and analysis of genetically modified rodents and cell lines. We offer the most comprehensive selection of services for transgenic and knockout mice and rats in the industry. Our distinct portfolio of services combined with our expertise, commitment to excellence and affordable pricing make TransViragen a valued resource for our clients' research model needs.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2011

Contact: Leena Bhoite, Ph.D., 801-213-3581

Website: http://www.transviragen.com

x

Startup: University Innovation Services

Technology Description: University Innovation Services' product is WIN, a peer-to-peer software-as-service platform with a unique "no barriers" structure that allows users and resources to connect in a user-defined environment, either through member groups, by subscribing to specific labs, or by individual exploration of resources listed on the network.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2013

Contact: Olena Gligorich, Ph.D., 801-213-3578

x

Startup: Utah Medical Solutions

Technology Description: Utah Medical Solutions (UMS) systems deliver disease-specific information allowing clinicians to interface with an electronic patient record and allowing patients to interface and track real-time symptoms and response to treatments.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2012

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.utahmedicalsolutions.com

x

Startup: Vaporsens

Technology Description: Whether it be a soldier looking for explosives on a suspect's hands, a highway patrol officer sensing a car for trace amounts of narcotics, or the border security sniffing cargo trucks, the Vaporsens sensing technology can assist these public servants unlike any currently available technology. Vaporsens, is developing a detector to help public safety officials sniff out explosives and narcotics using a patented sensor that is more sensitive than any other on the market. It's an "electronic dogs nose".

Technology Status: Prototype

Current Investors: PLUS550, Chemical Angels

Investment Stage: Series-A

Management Team: Benjamin Rollins, Ling Zang

Year Founded: 2012

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.vaporsens.com

x

Startup: Veristride

Technology Description: Veristride's initial product includes instrumentation worn on the shoes and a phone application for user feedback. The phone app collects data wirelessly from insole system and provides feedback corresponding to the symmetry of gait. The user can set the target symmetry and allowed range.

Technology Status: Scalable prototype / pre-clinical

Current Investors: Proprietary Information

Investment Stage: Pre-seed

Funding Round: Angel FUnding, Fall 2014

Management Team: Stacy Morris Bamberg, Fred Jaeger, Affiliated Management

Year Founded: 2012

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://veristride.com

x

Startup: Veritract

Technology Description: Each year approximately 3,000 people in the US die because of incorrectly placed feeding tubes. Veritract is developing feeding tubes with integrated optics and steering allowing precision tube placement and confirmation in the GI tract through direct vision. Our technology can be utilized to prevent unnecessary deaths or serious complications.

Technology Status: Scalable prototype (applications for EMEA and FDA approval submitted)

Current Investors: KickStart, UpStart, Molecular Cloud, Salt Lake Life Sciences Angels

Investment Stage: Series A2

Management Team: Dr. John Fang- Founder and CSO; Hunter Jackson, PhD- CEO; Brandi Simpson- CBO; Tim Nieman- COO

Year Founded: 2010

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

Website: http://www.veritract.com

x

Startup: Versa Power Systems

Year Founded: 2002

Acquirer: Fuel Cell Energy

Website: www.fuelcellenergy.com

x

Startup: Verus Mobile Security

Technology Description: Verus Mobile Security, LLC offers a mobile device authentication software solution that makes mobile access to secure databases both more secure and more convenient. Our security software is specifically designed to allow mobile apps to function in conjunction with the EPIC and Centricity electronic medical record systems.

Technology Status: In market

Current Investors: Proprietary Information

Investment Stage: Pre-seed

Management Team: Brian Innes, Sam Hickcox, Craig Swapp, Dr. Kevin Wethington

Year Founded: 2013

Funding Round: Pre-seed, Summer-Fall 2014

Contact: John Gebhard, Ph.D., 801-213-3564

Website: http://verusmobile.wordpress.com/

x

Startup: Vestan Medical Imaging

Technology Description: One million operations for suspected cases of breast cancer are performed every year in the United States. While only twenty percent of those operations show that there is actual cancer in the breast, the other 80% find no cancer. Over one third of patients with malignant tumors who go in for a lumpectomy procedure end up needing a second surgery to remove additional cancer that was not identified in the first operation. Vestan's technology will empower surgeons with new imaging techniques to aid in the visualization of tumors and lymph nodes in the operating room. After injection of the imaging drug, using the developed instrumentation, the cancerous tissue glows brightly helping surgeons easily identify where the cancer stops and where the healthy tissue begins. Doctors can help preserve healthy tissue because they no longer have to rely on old fashioned measures to identify the cancerous tissue during surgery.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2006

Contact: Richard L. Green, Ph.D., JD, 801-213-3573

Website: http://www.vestan-med.com/

x

Startup: Vettore

Technology Description: Vettore is focused on the development of therapeutics targeting key regulators of cellular metabolism and homeostasis, with the goal of producing significant new treatment options for a number of diseases, including cancer, type 2 diabetes, and neurological disorders.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2013

Contact: Beth Drees, Ph.D., MBA, 801-585-5016

x

Startup: ViroPan

Technology Description: ViroPan's "VR101" lubricating intravaginal ring is a market disruptive product that is under development to treat vaginal dryness, atrophy, irritation, and discomfort. A human pilot study recently was completed using VR101 and the preliminary data are very encouraging (participants stated, "I wish it were available right now!" and "It made me feel alive again!"). Each ring is intended to provide moisturizing relief for up to seven days, and to enhance the ease and comfort of intimate sexual activity, without the use of drugs or hormones. It is a clear flexible ring made of a biomedical grade elastomer that releases a moisturizing fluid. VR101 is an ideal alternative to currently available products. The Company plans for the ring to be available over-the-counter (OTC) with global distribution. We are seeking a strategic partner to help finalize the commercialization of VR101, including expertise and financing for manufacturing scale-up, development, regulatory, and additional biocompatibility testing to support the pivotal clinical study, as well as support for operational and product development activities necessary to achieve FDA 510(k) clearance and market launch.

Technology Status: Phase 3

Current Investors: Salt Lake Life Science Angels, Private Investors, Founders

Investment Stage: Series A

Funding Round: Series A, Summer 2014

Management Team: Tyler McCabe, PhD, MSPH – President/CEO/Director, 25+ years senior management and scientific roles, Co-founder MNKD (NASDAQ)/Director, 5 drugs and 4 medical devices into clinic, start-ups, IVD 510(k), preclinical/clinical R&D, medical devices, $25M raised, Co-inventor; Tim Glassett, JD, MBA – Chairman/Director, Former General Counsel of consumer focused corporations, 30 years corporate and M&A law; DJ Lee, MD, PhD, MPH – CMO/Director, 25+ years, Prof/Head, Dept. Family Practice and Community Health Center for Health Promotion and Aging, Ajou Univ. School of Medicine Clinical, start-ups; Larry Rigby, MA – Director, Founder SLLSA, CEO Larada, 30 years medical devices

Year Founded: 2008

Website: www.viropan.com

Contact: James E. Thompson, M.S., 801-213-3564

x

Startup: VisTrails, LLC

Technology Description: VisTrails, Inc. is at the forefront of provenance management research and technology development. The new functionalities that we bring to market will revolutionize the way people explore, analyze, and create data products. One of the greatest challenges of the 21st century is to effectively understand and leverage the growing wealth of digital data. Be it to mine the data or to create insightful visualizations, animations, or simulations, complex multi-step computational processes are required. The VisTrails software system is a new provenance management system that provides breakthrough technology for data exploration, creation, visualization and analysis. Although VisTrails was originally built to address the needs of exploratory scientific applications, the infrastructure it provides is general and applicable to a wide range of information technologies and applications.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2008

Website: http://www.vistrails.com

Contact: Timothy Tripp, JD, 801-581-8057

x

Startup: Visual Influence

Year Founded: 2002

Acquirer: Numira

Website: http://numira.com

x

Startup: Visual Share, LLC

Technology Description: VisualShare provides software solutions for image exchange, management and collaboration. VisualShare applications are for organizations that need to share images, conduct reviews and document results. The company products establish a framework to support image-centric collaboration and sharing. The technology platform and framework stores all collected information in a single record that can be re-used for many stakeholder requirements, such as internal or external reviews, quality assurance/quality control, audit, and evidentiary logging purposes.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2006

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.visualshare.com

x

Startup: Visus Technology

Technology Description: Visus technologies enable scalable storage, processing and delivery of high-resolution images. These technologies have the ability to be scalable across a wide range of computing resources, and performance degrades very gracefully on low- power/low-performance devices. Application areas include digital photography, interactive entertainment, intelligence and remote medicine.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2012

Contact: Timothy Tripp, JD, 801-581-8057

Website: http://www.visustech.com

x

Startup: Voyant Biotherapeutics

Technology Description: Voyant Biotherapeutics was founded to commercially develop diagnostics and therapeutics in the treatment of Age-Related Macular Degeneration (AMD).

Technology Status: Research & Development Phase

Current Investors: Proprietary information

Investment Stage: Proprietary information

Management Team: Dr. R Dana Ono

Year Founded: 2012

Acquirer: Allergan

Contact: John Gebhard, Ph.D., 801-213-3564

x

Startup: Vutara

Technology Description: Vutara's SR-350 microscope defines the cutting edge in super-resolution technology. Utilizing advanced 3D imaging techniques and Vutara's ResEnhanced technology, the SR-350 enables you to acquire super-resolved images in seconds. Vutara's paradigm shifting technology redefines super-resolution microscopy broadening sample configuration options.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2010

Contact: Richard L. Green, Ph.D., JD, 801-213-3573

Website: http://vutara.com

x

Startup: Wasatch Microfluidics, Inc.

Technology Description: Wasatch Microfluidics, LLC (Wasatch) develops pharmaceutical research devices that enable significant advances in the rapidly growing microarray markets. Wasatch's Continuous Flow Microspotter (CFM) technology uses flow to print microarray spots. The CFM uses microchannels the size of a human hair to flow protein solutions over a surface. This allows more proteins to attach to the surface, thereby leveraging precious samples and allowing researchers to achieve dramatically enhanced sensitivity. Currently, researchers must purify their samples using a process that can take up to weeks of technician time and hundreds of dollars in consumables. The CFM allows researchers to flow a non-purified sample over the surface and "fish" the molecule of interest out of the mixture. For companies with large development libraries, the cost savings will be highly significant.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2006

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.microfl.com

x

Startup: Waste Water Compliance Systems

Technology Description: We manufacture and sell patented, submerged, aerated bio-reactors (Bio-Shells) for wastewater lagoons that enable communities to economically stay in compliance. The Bio-Shells use are energy efficient and use naturally occurring bacteria to remediate wastewater. Additional units can be installed on an incremental basis as a community grows to exactly match supply with regulatory demands.

Technology Status: In market

Current Investors: KickStart & Park City Angels (Series A)

Investment Stage: Pre-Series B

Funding Round: Series B, 2015

Management Team: Al Rafati (investor), Kraig Johnson PhD, Larry Reaveley PhD, Fred Jaeger MBA

Year Founded: 2009

Contact: James E. Thompson, M.S., 801-213-3564

Website: http://www.wcs-utah.com

x

Startup: Xandem

Technology Description: Xandem Technology detects and locates people who are not carrying a tag or device. This powerful and cost-effective technology can detect people through walls, obstructions and in other difficult environments. Xandem surrounds areas with small, inexpensive and low-power wireless transceivers. The devices communicate with one another to form a dense web of radio waves that blanket the area. When people enter the area, their bodies disturb the radio field and Xandem technology detects and locates them.

Technology Status:

Current Investors:

Investment Stage:

Management Team:

Year Founded: 2011

Contact: Sripriya Raghavendran, MSEE, 801-585-3610

Website: http://www.xandem.com

x

Startup: XEnd

Technology Description: XEnd Medical Systems mission is to reduce the incidence of infections caused by hypodermic needle injections. Invented by a world-renowned eye surgeon, the "Antibacterial Hypodermic Needle and Syringe (AHNS)" is designed to prevent bacteria on the surface from being transported to the body's interior by a hypodermic needle. This is a serious problem for patients receiving injections of medication into spaces with little ability to fight infection, including the eye, certain joints, cerebrospinal fluid and any injection where the patient is severely immunosuppressed. Bodily fluids withdrawn via needle and syringe are also susceptible to bacterial infection, causing a serious, prevalent and costly problem for physicians performing blood cultures. The AHNS is expected to drive better patient outcomes and to sharply lower treatment and liability costs.

Technology Status: Pre-prototype

Current Investors: Actively seeking to raise a $300k seed round

Investment Stage: Pre-seed stage

Funding Round: Actively seeking to raise a $300k seed round

Management Team: President & CEO: Andrew Raguskus; Chief Medical Officer: Randall Olson, MD

Year Founded: 2011

Contact: John Gebhard, Ph.D., 801-213-3564

x

Startup: Xenocor

Technology Description: Xenocor is a surgical medical device start-up developing a low-cost laparoscopic camera system and accessory technology for low-resource settings. This is expected to benefit developing nations, rural areas, and military settings.

Year Founded: 2014

Contact: Leena Bhoite, Ph.D., 801-213-3581

x

Startup: Zars

Year Founded: 1998

Acquirer: Nuvo Research

Website: www.nuvoresearch.com